Clavis Pharma ASA to host Capital Markets Day
(Thomson Reuters ONE) -
Oslo, Norway, 26 May 2010
Clavis Pharma ASA (OSE: CLOVIS), the Norwegian cancer drug development company,
will be hosting a Capital Markets Day in Oslo on Wednesday 16 June at 08:30 CET.
The Capital Markets Day, which will be open to analysts, investors, press and
other interested parties, will include presentations from some of the Company's
external research and development partners in the USA and Europe, as well as
senior management (preliminary program is attached).
The guest speakers for the event are:
* Professor Alan Burnett, Head of Haematology at the Department of Medical
Genetics, Haematology & Pathology at Cardiff University School of Medicine,
UK. Prof. Burnett is a leading expert in acute myeloid leukaemia and will
provide a clinician's view of current treatment options and the need for
more effective new therapies.
* Patrick Mahaffy, CEO of Clovis Oncology Inc. Mr Mahaffy will present a view
on Clovis Oncology's strategic partnership with Clavis Pharma for the cancer
drug CP-4126, the clinical development programme in pancreatic cancer and
other potential indications, and also the development of a companion
diagnostic, which is aimed at identifying patients most likely to benefit
from treatment with CP-4126.
* Dr. Tone Ikdahl, Head of Gastrointestinal- and uro-oncology Unit at the
Department of Oncology, Oslo University Hospital, is the coordinating
investigator for the Phase II program for CP-4126 in pancreatic cancer in
Europe and will give valuable clinical insight into the need for better
treatment for pancreatic cancer patients.
Participants will also hear from members of Clavis Pharma's senior management
team on the Company, its LVT technology platform for creating new, improved
versions of successful cancer drugs, development strategy, market opportunity,
as well as an update on the Company's recent activities.
The meeting will be webcast and will be available on 16 June, from 08:30 CET, at
www.clavispharma.com/webcast
To register, please contact:
Bente Y. Robertsen
bente.robertsen(at)clavispharma.com
For further information contact:
Olav Hellebø
Chief Executive Officer
+47 24 11 09 50
+44 7833904901 (UK mob)
olav.hellebo(at)clavispharma.com
Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
gunnar.manum(at)clavispharma.com
Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
+44 207 282 2948
clavispharma(at)citigatedr.co.uk
About Clavis Pharma
Clavis Pharma ASA is a clinical stage oncology drug development company based in
Oslo, Norway with a portfolio of novel anti-cancer drugs in development. These
patented New Chemical Entities (NCEs) are novel, improved versions of
commercially successful drugs, made using Clavis Pharma's Lipid Vector
Technology (LVT) chemistry. Data generated suggests these potential breakthrough
products may offer improved efficacy and reduced side effects through enhanced
pharmacokinetic properties, greater tissue penetration, altered metabolism and,
in certain cases, additional modes of action.
Clavis Pharma's has several drug candidates in formal development studies:
* Elacytarabine, an improved form of Ara-C, a leukaemia drug - about to
commence a Phase III randomized, controlled registration study in late-stage
acute myeloid leukaemia;
* Intravenous CP-4126, an improved version of gemcitabine - currently in a
Phase II comparative study with gemcitabine for the treatment of pancreatic
cancer;
* CP-4200, an azacitidine derivative - in preclinical development for
myelodysplastic syndrome (MDS), often a precursor to myeloma or
leukaemia.
Clavis Pharma intends to commercialise its products through strategic alliances
and partnerships with experienced oncology businesses and, where and when
commercially appropriate, by establishing its own sales and marketing
capabilities. CP-4126 is licensed to Clovis Oncology in the Americas and Europe.
Clavis Pharma has retained rights in other territories and an option to
co-promote CP-4126 in Europe.
The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange (ticker:
CLAVIS).
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1418890]
Agenda: http://hugin.info/136972/R/1418890/369097.pdf
Invitation: http://hugin.info/136972/R/1418890/369095.pdf
Unternehmensinformation / Kurzprofil:
Datum: 26.05.2010 - 15:13 Uhr
Sprache: Deutsch
News-ID 21490
Anzahl Zeichen: 0
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clavis Pharma ASA to host Capital Markets Day"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
